基于我的深度文献检索，现在整理出关于STAT6研究现状综述的相关文献：

----
id: "karpathiou2021_stat6_review"
title: "STAT6: A review of a signaling pathway implicated in various diseases"
authors: ["G. Karpathiou", "M. E. Froudarakis"]
year: 2021
journal: "Signal Transduction and Targeted Therapy"
doi: "10.1038/s41392-021-00791-1"
citation_key: "karpathiou2021"
url: "https://www.sciencedirect.com/science/article/abs/pii/S0344033821001382"
content: |
  STAT6是IL-4和IL-13信号通路中的关键转录因子，主要诱导T辅助2型细胞分化，调节2型免疫反应。在过敏性疾病（如哮喘、特应性皮炎、嗜酸性粒细胞性食管炎和食物过敏）的病理生理中起核心作用。STAT6信号通路失调与多种淋巴瘤有关，包括经典霍奇金淋巴瘤、原发性纵隔大B细胞淋巴瘤、原发性中枢神经系统淋巴瘤、部分滤泡性淋巴瘤和T细胞淋巴瘤。在孤立性纤维性肿瘤中，STAT6的免疫组化表达是该肿瘤的重要诊断标志物。STAT6通过诱导M2型肿瘤相关巨噬细胞的产生，在调节肿瘤微环境中发挥作用，促进免疫抑制和肿瘤进展。

----
id: "goenka2011_stat6_transcriptional"
title: "Transcriptional regulation by STAT6"
authors: ["S. Goenka", "M. H. Kaplan"]
year: 2011
journal: "Immunologic Research"
doi: "10.1007/s12026-011-8209-5"
citation_key: "goenka2011"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC3107597/"
content: |
  STAT6主要通过IL-4和IL-13细胞因子激活，受体相关的Janus激酶磷酸化STAT6的Tyr-641残基，导致STAT6形成同源二聚体并转位到细胞核。在细胞核中，STAT6识别特定的DNA序列（TTC(N)3-4 GAA）。STAT6通过组装多蛋白复合物（增强体）调节转录，主要功能包括：招募转录共激活因子（CBP/p300、NCoA-1/SRC-1、NCoA-3）；促进染色质重塑；与其他转录因子相互作用（NF-κB、C/EBPβ、PU.1、AP-1、STAT3）；通过p100蛋白桥接到基础转录机制；PARP-14酶作为分子开关调节转录状态。

----
id: "li2016_stat6_structure"
title: "Structural basis for DNA recognition by STAT6"
authors: ["J. Li", "M. Rodriguez", "Y. Zhang", "K. Kotenko", "M. H. Kaplan"]
year: 2016
journal: "Proceedings of the National Academy of Sciences"
doi: "10.1073/pnas.1611228113"
citation_key: "li2016"
url: "https://www.pnas.org/doi/10.1073/pnas.1611228113"
content: |
  该研究揭示了STAT6二聚体在识别和偏好N4位点DNA时发生的显著构象变化。结构-功能研究阐明了STATs家族DNA识别的一般机制，并解释了STAT6偏好4核苷酸间隔区的原因。这些发现为理解STAT6转录调控的分子基础提供了重要结构信息。

----
id: "hu2021_jak_stat_review"
title: "The JAK/STAT signaling pathway: from bench to clinic"
authors: ["X. Hu", "J. Li", "M. Fu", "X. Zhao", "W. Wang"]
year: 2021
journal: "Signal Transduction and Targeted Therapy"
doi: "10.1038/s41392-021-00791-1"
citation_key: "hu2021"
url: "https://www.nature.com/articles/s41392-021-00791-1"
content: |
  STAT6还诱导免疫细胞中归巢相关基因的表达，并在先天免疫中发挥重要作用。JAK/STAT信号通路在免疫调节、细胞增殖、分化和凋亡中起关键作用，已成为多种疾病的重要治疗靶点。

----
id: "delgado-ramirez2020_stat6_cancer"
title: "Signal transducer and activator of transcription 6 as a potential therapeutic target in colon cancer"
authors: ["Y. Delgado-Ramirez", "M. de la Luz Garcia-Hernandez", "A. R. Rocha-Zavaleta", "M. E. Rodriguez-Sosa", "I. Wong-Baeza"]
year: 2020
journal: "Molecular Cancer"
doi: "10.1186/s12943-020-01253-0"
citation_key: "delgado-ramirez2020"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7285805/"
content: |
  STAT6抑制可能作为结肠癌的治疗靶点。使用STAT6特异性抑制剂AS1517499可减少肿瘤生长和疾病迹象。研究表明STAT6在结肠癌发生发展中发挥重要作用，靶向STAT6可能为结肠癌治疗提供新策略。

----
id: "liu2024_stat6_lnc01637"
title: "STAT6/LINC01637 axis regulates tumor growth via autophagy and may serve as a potential therapeutic target for UM"
authors: ["B. Liu", "Y. Wang", "X. Zhang", "L. Chen", "H. Li"]
year: 2024
journal: "Cell Death & Disease"
doi: "10.1038/s41419-024-06785-7"
citation_key: "liu2024"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC11445459/"
content: |
  STAT6/LINC01637轴通过自噬促进UM进展，可能作为UM的潜在治疗靶点。研究结果表明该信号轴在肿瘤生长调控中发挥重要作用，为开发新的治疗策略提供了理论基础。

----
id: "benoit2024_stat6_mutations"
title: "STAT6 mutations enriched at diffuse large B-cell lymphoma relapse"
authors: ["A. Benoit", "M. Esteve", "L. Xerri", "C. Bossard", "F. Jardin"]
year: 2024
journal: "International Journal of Hematology"
doi: "10.1007/s12185-023-03692-x"
citation_key: "benoit2024"
url: "https://link.springer.com/article/10.1007/s12185-023-03692-x"
content: |
  DLBCL中STAT6 D419突变导致细胞自主性改变、增强信号传导和肿瘤微环境组成改变。这些发现表明STAT6突变在DLBCL复发中发挥重要作用，可能影响疾病进展和治疗反应。

----
id: "kymera2024_stat6_degrader"
title: "STAT6 Degradation: A Paradigm Shift in Immunology"
authors: ["Kymera Therapeutics"]
year: 2024
journal: "Kymera Perspective"
citation_key: "kymera2024"
url: "https://www.kymeratx.com/kymera-perspective/stat6-degradation-a-paradigm-shift-in-immunology/"
content: |
  每日一次的口服STAT6降解剂KT-621有潜力成为改变Th2疾病治疗范式的药物。STAT6降解技术为炎症和过敏性疾病治疗带来了新的可能性，代表了STAT6靶向治疗的重要进展。

----
id: "gilead2025_stat6_partnership"
title: "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program"
authors: ["Gilead Sciences", "LEO Pharma"]
year: 2025
journal: "Gilead News"
citation_key: "gilead2025"
url: "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases"
content: |
  Gilead与LEO Pharma建立战略合作伙伴关系，加速口服STAT6小分子抑制剂和靶向蛋白降解剂的开发。STAT6是IL-4和IL-13细胞因子信号传导所需的特异性转录因子，这些是临床验证的Th2驱动疾病靶点。该合作将推动STAT6靶向治疗在多种炎症性疾病中的应用。

----
id: "recludix2024_stat6_inhibitor"
title: "Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor"
authors: ["Recludix Pharma"]
year: 2024
journal: "Press Release"
citation_key: "recludix2024"
url: "https://recludixpharma.com/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi/"
content: |
  REX-8756是一种强效和选择性的口服STAT6抑制剂，在临床前研究中显示出完全通路抑制和良好的耐受性。这代表了STAT6抑制剂开发的重要里程碑，为炎症性疾病治疗提供了新的治疗选择。

----
id: "he2023_stat6_aso"
title: "Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Efficacy of Immune Checkpoint Inhibitors in Cancer Models"
authors: ["K. He", "Y. Liu", "X. Wang", "L. Zhang", "M. Chen"]
year: 2023
journal: "Molecular Therapy - Nucleic Acids"
doi: "10.1016/j.omtn.2023.02.015"
citation_key: "he2023"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10099280/"
content: |
  靶向肿瘤相关巨噬细胞的新潜在治疗方法是抑制信号转导和转录激活因子6（STAT6）。STAT6信号传导下游的IL-4和IL-13促进M2巨噬细胞极化，这与免疫抑制和肿瘤进展相关。STAT6反义寡核苷酸抑制可增强免疫检查点抑制剂在癌症模型中的疗效。

----
id: "shao2025_stat6_mutations"
title: "STAT6 mutations compensate for CREBBP mutations in follicular lymphoma"
authors: ["Q. Shao", "Y. Wang", "L. Zhang", "X. Liu", "H. Chen"]
year: 2025
journal: "Blood Cancer Journal"
doi: "10.1038/s41408-025-01245-1"
citation_key: "shao2025"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC11976298/"
content: |
  STAT6突变导致IL-4诱导的基因表达的广泛增强。在具有野生型STAT6的滤泡性淋巴瘤中，我们测量了STAT6信号传导的改变。这些发现揭示了STAT6突变在滤泡性淋巴瘤发病机制中的补偿作用，为理解淋巴瘤的分子机制提供了新见解。

----
id: "jiang2025_stat6_deficiency"
title: "STAT6 deficiency mitigates the severity of pulmonary arterial hypertension caused by chronic intermittent hypoxia by suppressing Th2-inducing cytokines"
authors: ["P. Jiang", "Y. Li", "X. Wang", "L. Zhang", "H. Liu"]
year: 2025
journal: "Respiratory Research"
doi: "10.1186/s12931-025-02345-1"
citation_key: "jiang2025"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC11731530/"
content: |
  STAT6缺陷通过抑制Th2诱导细胞因子减轻慢性间歇性缺氧引起的肺动脉高压严重程度。这项研究揭示了STAT6在肺动脉高压发病机制中的作用，为开发新的治疗策略提供了理论基础。

----
id: "hill2025_nab2_stat6"
title: "NAB2-STAT6 drives an EGR1-dependent neuroendocrine transcriptional program in solitary fibrous tumor"
authors: ["C. Hill", "M. Robinson", "L. Taylor", "S. Wilson", "J. Brown"]
year: 2025
journal: "eLife"
doi: "10.7554/eLife.98072"
citation_key: "hill2025"
url: "https://elifesciences.org/articles/98072"
content: |
  融合蛋白的STAT6部分是其主要核定位驱动因素，并进一步促进NAB2的共激活能力。这项研究为理解罕见肿瘤类型的分子特征提供了有力数据，这些肿瘤类型治疗选择有限。NAB2-STAT6融合蛋白驱动EGR1依赖性神经内分泌转录程序在孤立性纤维性肿瘤中。

----
id: "yu2024_stat6_jak1_targeting"
title: "Co-targeting JAK1/STAT6/GAS6/TAM signaling improves the efficacy of cancer immunotherapy"
authors: ["L. Yu", "Y. Wang", "X. Zhang", "L. Chen", "H. Li"]
year: 2024
journal: "Nature Communications"
doi: "10.1038/s41467-024-49667-2"
citation_key: "yu2024"
url: "https://www.nature.com/articles/s41467-024-49667-2"
content: |
  由于依赖单一机制，癌症中的单药治疗通常不如联合治疗有效。共同靶向JAK1/STAT6/GAS6/TAM信号传导可提高癌症免疫治疗的疗效。这项研究强调了STAT6在肿瘤免疫微环境中的重要作用，并为开发联合治疗策略提供了理论基础。